M31.2
Lethal midline granuloma
Clinical Classification Guidelines
Medical Intelligence & Overview
Lethal midline granuloma, known medically as granulomatosis with midline destructive lesions, is a rare and severe disorder characterized by the progressive destruction of tissues in the midface, including the nose, sinuses, palate, and surrounding structures. It often presents with painless, destructive lesions that can rapidly worsen if not properly diagnosed and managed, leading to significant disfigurement and functional impairments. Historically, this condition was thought to be a form of malignancy or a specific infectious process, but now it is classified as a form of extranodal natural killer (NK)/T-cell lymphoma, highlighting its neoplastic and immunological nature.
Causes & Symptoms
Clinical Causes: Associated with Epstein-Barr Virus (EBV) infection Potentially linked to autoimmune or immunodeficiency conditions Certain genetic predispositions may contribute Environmental factors, such as exposure to particular chemicals or irritants, might influence development
Key Symptoms: Nasal congestion, often persistent and unresponsive to typical treatments Nasalbleeding or epistaxis Ulceration or erosion of the nasal palate and surrounding tissues Facial swelling or deformity due to tissue destruction Persistent nasal discharge, which may be bloody Difficulty breathing through the nose Ex facial swelling and ulceration in advanced cases Weight loss and general fatigue in systemic involvement Palatal perforation creating an oronasal fistula
Diagnostic & Treatment
Diagnosis Path: Detailed medical history and physical examination focusing on nasal and midface regions Imaging techniques such as CT scans or MRI to assess the extent of soft tissue and bone destruction Biopsy of affected tissue for histopathological examination Immunohistochemical studies to identify the specific type of lymphoid cells involved Serological tests for EBV DNA to support the association Laboratory tests to rule out infectious causes or other inflammatory conditions
Treatment Protocols: Chemotherapy protocols tailored for extranodal NK/T-cell lymphoma, often including agents such as CHOP or other combination regimens Radiation therapy to target localized lesions and reduce tumor burden Immunotherapy approaches, such as the use of antiviral agents or monoclonal antibodies, in some cases Surgical interventions to remove necrotic tissue or repair structural damage, usually as supportive measures Supportive care including management of infections, nutritional support, and pain relief Regular follow-up for disease monitoring and early detection of recurrence
Clinical Advice & FAQs
Billing Guidance
Is M31.2 a billable ICD-10 code?
Yes, M31.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M31.2?
Clinical documentation must specify the nature of Lethal midline granuloma and any associated comorbidities for accurate reporting.
Cite this Clinical Reference